Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions 
Italy Fines Apple €98.6 Million Over App Store Dominance 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026 
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling 
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
OSLO, Norway, May 31, 2016 -- Targovax, a clinical stage immuno-oncology company, developing targeted immunotherapy treatments for cancer patients, announces that members of its senior management team will participate in the following life sciences and investor conferences:
Redeye Investor Forum
Stockholm, 1 June 2016
Participants: Magnus Jäderberg (CMO)
Presentation time: 18:00
Venue: Redeye HQ, Mäster Samuelsgatan 42, Stockholm
Redeye Investor Forum
Västerås, 7 June 2016
Participants: Magnus Jäderberg (CMO)
Presentation time: 19:30
Venue: Elite Stadshotellet, Stora Torget, Västerås
Småbolagsdagen 2016
Stockholm, 13 June 2016
Participants: Gunnar Gårdemyr (CEO)
Presentation time: 17:00 (Room 2 - Life Science)
Venue: Sheraton Stockholm Hotel, Tegelbackan 6, Stockholm
BIO International Convention
San Francisco, 6-9 June 2016
Participants: Gunnar Gårdemyr (CEO) and Peter Skorpil (VP Business Development)
The presentations will be available to download at www.targovax.com following the event.
For further information, please contact:
Gunnar Gårdemyr, CEO
Phone: +46 73 083 77 79
Email: [email protected]
Øystein Soug, CFO
Phone: +47 906 56 525
Email: [email protected]
Arming the patient's immune system to fight cancer
Targovax is a clinical stage immuno-oncology company developing targeted immunotherapy treatments for cancer patients. Targovax has a broad and diversified immune therapy portfolio and aims to become a world leader in its area. The company is currently developing two complementary and highly targeted approaches in immuno-oncology.
ONCOS - 102 is a virus-based immunotherapy platform based on engineered oncolytic viruses armed with potent immune-stimulating transgenes targeting solid tumors. This treatment is designed to reactivate the immune system's capacity to recognize and attack cancer cells.
TG01 and TG02 are part of a peptide-based immunotherapy platform targeting the difficult to treat RAS mutations found in more than 85% of pancreatic cancers, 50% of colorectal cancer and 20-30% of all cancers. Targovax is working towards demonstrating that TG vaccines will prolong time to cancer progression and increase survival.
These product candidates will be developed in combination with multiple treatments, including checkpoint inhibitors in several cancer indications. Targovax also has a number of other cancer immune therapy candidates in the early stages of development.
HUG#2016583
